Real-World Use and Acceptance of Biosimilar Monoclonal Antibodies of Rituximab in Oncology Practice in the USA

References

• FDA . ‘Biosimilar and interchangeable products’ (2017). www.fda.gov/drugs/biosimilars/biosimilar-and-interchangeable-products
   Google Scholar
• FDA . ‘Biosimilars’ (2020). www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilars
   Google Scholar
• Calvo B , ZuñigaL. The US approach to biosimilars. BioDrugs26(6), 357–361 (2012).
   PubMed Web of Science ®Google Scholar
• Nabhan C , ParsadS, MatoAR, FeinbergBA. Biosimilars in oncology in the United States: a review. JAMA Oncol.4(2), 241 (2018).
   PubMed Web of Science ®Google Scholar
• Cortes J , Perez-GarcíaJM, Llombart-CussacAet al. Enhancing global access to cancer medicines. CA Cancer J. Clin.70(2), 105–124 (2020).
   PubMed Web of Science ®Google Scholar
• Mulcahy AW , HlavkaJP, CaseSR. Biosimilar cost savings in the United States: initial experience and future potential. Rand. Heal. Q.7(4), 3 (2018).
   PubMedGoogle Scholar
• Grillo-Lopez A , WhiteC, DallaireBet al. Rituximab the first monoclonal antibody approved for the treatment of lymphoma. Curr. Pharm. Biotechnol.1(1), 1–9 (2000).
   PubMedGoogle Scholar
• Wierda WG , ByrdJC, AbramsonJSet al. Chronic lymphocytic leukemia/small lymphocytic lymphoma, Version 4.2020, NCCN clinical practice guidelines in oncology. J. Natl Compr. Canc. Netw.18(2), 185–217 (2020).
   PubMed Web of Science ®Google Scholar
• Casak SJ , LemerySJ, ShenYLet al. US Food and Drug Administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia. Oncologist16(1), 97–104 (2011).
   PubMed Web of Science ®Google Scholar
• Rioufol C , SallesG. Biosimilar monoclonal antibodies in lymphoma: a critical appraisal. Expert Rev. Anticancer Ther.15(5), 569–578 (2015).
   PubMed Web of Science ®Google Scholar
• Rugo HS , LintonKM, CerviP, RosenbergJA, JacobsI. A clinician’s guide to biosimilars in oncology. Cancer Treat. Rev.46, 73–79 (2016).
   PubMed Web of Science ®Google Scholar
• Ngo D , ChenJ. A clinical review of biosimilars approved in oncology. Ann. Pharmacother.55(3), 362–377 (2021).
   PubMed Web of Science ®Google Scholar
• FDA . FDA approves first biosimilar for treatment of adult patients with non-Hodgkin's lymphoma. www.fda.gov/news-events/press-announcements/fda-approves-first-biosimilar-treatment-adult-patients-non-hodgkins-lymphoma
   Google Scholar
• FDA . Drug approval package: RUXIENCE. www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761103Orig1s000TOC.cfm
   Google Scholar
• Ogura M , CoiffierB, KwonH-C, YoonSW. Scientific rationale for extrapolation of biosimilar data across cancer indications: case study of CT-P10. Future Oncol.13(15s), 45–53 (2017).
   PubMedGoogle Scholar
• Dolan C . Opportunities and challenges in biosimilar uptake in oncology. Am. J. Manag. Care24(Suppl. 11), S237–S243 (2018).
   PubMed Web of Science ®Google Scholar
• Leonard E , WascovichM, OskoueiS, GurzP, CarpenterD. Factors affecting health care provider knowledge and acceptance of biosimilar medicines: a systematic review. J. Manag. Care Spec. Pharm.25(1), 102–112 (2019).
   PubMed Web of Science ®Google Scholar
• Otremba B , BorchardtJ, KuskeA, Hollnagel-SchmitzM, LoschFO. Real-world use and acceptance of rituximab biosimilars in non-Hodgkin lymphoma in an oncologist network in Germany. Future Oncol.16(15), 1001–1012 (2020).
   PubMed Web of Science ®Google Scholar
• Cuellar S , McBrideA, MedinaP. Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practice. Am. J. Heal. Pharm.76(21), 1725–1738 (2019).
   PubMed Web of Science ®Google Scholar
• Teeple A , EllisLA, HuffLet al. Physician attitudes about non-medical switching to biosimilars: results from an online physician survey in the United States. Curr. Med. Res. Opin.35(4), 611–617 (2019).
   PubMed Web of Science ®Google Scholar
• Jaffe DH , LeeL, HuynhS, HaskellTP. Health inequalities in the use of telehealth in the United States in the lens of COVID-19. Popul. Health Manag.23(5), 368–377 (2020).
   PubMed Web of Science ®Google Scholar
• Foster SA , BalkaranBL, Cambron-MellottMJet al. Demographic and clinical characteristics of prevention-eligible patients with migraine in the US: a linked national survey and administrative claims database study. Curr. Med. Res. Opin.37(3), 443–457 (2021).
   PubMed Web of Science ®Google Scholar
• Boikos C , FischerL, O’BrienD, VaseyJ, SylvesterGC, MansiJA. Relative effectiveness of adjuvanted trivalent inactivated influenza vaccine versus egg-derived quadrivalent inactivated influenza vaccines and high-dose trivalent influenza vaccine in preventing influenza-related medical encounters in US adults ≥65years during the 2017–2018 and 2018–2019 influenza seasons. Clin. Infect. Dis. (2021). ( Epub ahead of print:)
   Web of Science ®Google Scholar
• Cohen HP , BlauveltA, RifkinRM, DaneseS, GokhaleSB, WoollettG. Switching reference medicines to biosimilars: a systematic literature review of clinical outcomes. Drugs78(4), 463–478 (2018).
   PubMed Web of Science ®Google Scholar
• Lee K , HaJY, JungARet al. The clinical outcomes of rituximab biosimilar CT-P10 (Truxima®) with CHOP as first-line treatment for patients with diffuse large B-cell lymphoma: real-world experience. Leuk. Lymphoma61(7), 1575–1583 (2020).
   PubMed Web of Science ®Google Scholar
• Shim SC , Božić-MajstorovićL, BerrocalKasay Aet al. Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial. Rheumatology58(12), 2193–2202 (2019).
   PubMed Web of Science ®Google Scholar
• NCCN . Chronic lymphocytic leukemia (2019). www.nccn.org/patients/guidelines/content/PDF/cll-patient.pdf
   Google Scholar
• NCCN . Diffuse large B-cell lymphoma (2020). www.nccn.org/patients/guidelines/content/PDF/nhl-diffuse-patient.pdf
   Google Scholar
• Norbeck TB . Drivers of health care costs. A Physicians Foundation white paper – second of a three-part series. Mo. Med.110(2), 113–118 (2013).
   PubMedGoogle Scholar
• Mariotto AB , EnewoldL, ZhaoJ, ZerutoCA, YabroffKR. Medical care costs associated with cancer survivorship in the United States. Cancer Epidemiol. Biomarkers Prev.29(7), 1304–1312 (2020).
   PubMed Web of Science ®Google Scholar
• Lyman GH , ZonR, HarveyRD, SchilskyRL. Rationale, opportunities, and reality of biosimilar medications. N. Engl. J. Med.378(21), 2036–2044 (2018).
   PubMed Web of Science ®Google Scholar